Navigation Links
Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccine's Clinical & Regulatory Strategy
Date:1/3/2012

WORCESTER, Mass. and TORONTO, Jan. 3, 2012 /PRNewswire/ -- Generex Biotechnology Corporation (OTCBB: GNBT) today provided an update to the clinical development & regulatory strategy for its cancer vaccine, AE37.  Positive interim Phase 2b clinical data from the study in HER-2 expressing breast cancer subjects (presented last month at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) in San Antonio, Texas) has lead to an earlier-than-expected advancement in the overall development of AE37 for both breast and prostate cancer indications.

(Logo: http://photos.prnewswire.com/prnh/20110106/NY25057LOGO-b )

AE37 is a novel Ii-Key Hybrid-based HER-2/neu Peptide Vaccine designed to train the immune system, independent of HLA-type, to track down cancer cells throughout the body and destroy them.  The positive interim Phase 2b results, building upon completed pre-clinical and Phase I breast cancer studies, enables Antigen Express to move up the timing of key development and regulatory plans.  In particular, the company will organize an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) by the end of Q1 2012.  With the FDA's guidance, the Company will move into a pivotal Phase 3 clinical development program in women with loco-regional breast cancer that express low to moderate levels of HER2.  Parallel steps will be taken with the European Medicines Agency using the same Phase 2b results.  The Phase 2b is currently planned to enroll a total of 300 women and will continue as planned to provide additional valuable information on efficacy and safety of AE37 as the Company pursues its Phase 3 trial plans.

Dr. Eric von Hofe, Ph.D., President of Antigen Express, said: "While the number of patients with recurrent breast cancer is still too low to confirm statistical significance in this ongoing study, the approximate
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Breast Cancer Vaccine Being Developed by Generex Subsidiary Antigen Express to be Featured on Bloomberg Television Today
2. Leading Investigator to Present Clinical Data on Generex Oral-lyn™ at International Diabetes Federation Meetings in Dubai
3. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
4. Generex Makes Podium Presentation of Clinical Data on Generex Oral-lyn™ at European Association for the Study of Diabetes Annual Meeting
5. Generex Provides Update on Spinout of Antigen Express
6. Generex Augments Cash Position With Sales of Non-Essential Assets
7. Amarantus BioSciences and Generex Biotechnology Collaborate on Cell Therapy for Late Stage Diabetes
8. Generex Announces Publication of Studies with the Mayo Clinic Confirming and Extending the Antigen Express Ii-Key Platform Technology
9. Generex Announces U.S. Congressman Curt Weldon, Co-Founder of the Congressional Diabetes Caucus, to Champion Generex Initiatives in Asia and North America
10. Generex Provides Clarification of Facts
11. Generex Announces Results of Annual Stockholders Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Local veterinarian, Dr. Keith Clement, and ... candidates to participate in an investigational study of donor ... goal of this study is to determine if a ... two arthritically affected joints can help reduce pain and ... the current investigational study must be older than nine ...
(Date:8/29/2014)... MA (PRWEB) August 29, 2014 A ... in the biotech start-up dense realm of Boston-Cambridge, is ... and able investors. James Sherley, the Director of Boston’s ... increasing the local and national visibility of his company ... September 2013. , In addition to a social media ...
(Date:8/28/2014)... Nevada City, CA (PRWEB) August 28, 2014 ... and sanitation products for the food processing industry, is ... conducting a side-by side comparison of the E2 soap ... Q E2 Sanitizing Foam Soap . Hand hygiene ... pathogens in the food processing environment. Six key criteria ...
(Date:8/28/2014)... new research platform uses a laser to ... undergoing stress and heating, an approach likely ... microelectronics and batteries., This new technique, called ... heating and the surface stress of microscale ... discussed the merits of surface-stress influence on ...
Breaking Biology Technology:Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 2The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 3The Adult Stem Cell Technology Center, LLC Participates in Multiple Stem Cell and Regenerative Medicine Conferences Before Year End 4Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3
... Sept. 30 DOR BioPharma, Inc. (OTC Bulletin Board: SNGX), ... a corporate name change from DOR BioPharma, Inc. to Soligenix, ... name change, the Company,s shares of common stock will immediately ... today. , "We are pleased to announce the ...
... 30 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT) ... and commercializing products for the treatment of cancer, ... of late-stage immunotherapy product candidates from Paladin Labs ... candidates consists of five monoclonal antibodies targeting certain ...
... , ... application enables system access and security for federal employees, regardless of location , ... Miami, FL (PRWEB) September ... landmark partnership with the Ministry of Health in Spain, providing the agency with software-based ...
Cached Biology Technology:DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol 'SNGX' 2DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol 'SNGX' 3DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol 'SNGX' 4Quest PharmaTech Acquires Late-Stage Immunotherapeutic Antibody Pipeline 2Quest PharmaTech Acquires Late-Stage Immunotherapeutic Antibody Pipeline 3Quest PharmaTech Acquires Late-Stage Immunotherapeutic Antibody Pipeline 4Spain's Health Ministry Contracts Authenware to Fortify System Security Prior to Flu Season 2Spain's Health Ministry Contracts Authenware to Fortify System Security Prior to Flu Season 3
(Date:9/1/2014)... has improved steadily in recent yearsspurred in large part ... poor and disparities continue to widen among socioeconomic and ... School of Public Health (HSPH). , "The study provides ... efforts by many groups and individuals to improve U.S. ... indicates that these efforts need to be expanded," said ...
(Date:9/1/2014)... 2014, 10:20 AM EDT) It may be possible ... over unhealthy higher-calorie foods, according to new research by ... Center on Aging (USDA HNRCA) at Tufts University and ... journal Nutrition & Diabetes , a brain scan ... is possible to reverse the addictive power of unhealthy ...
(Date:9/1/2014)... and decisions of the Nomenclature Section of the XVIII ... July 2011. This meeting is held every six years ... the rules for naming algae, fungi and plants get ... naming the organisms they study. This is the primary ... for algae, fungi, and plants, which was published in ...
Breaking Biology News(10 mins):Quality of US diet shows modest improvement, but overall remains poor 2Quality of US diet shows modest improvement, but overall remains poor 3Training your brain to prefer healthy foods 2Week-long meeting on naming algae, fungi, and plants recorded for posterity 2
... microbe samples while preserving the microbes, natural gene expression ... varieties of small RNAs snippets of RNA that ... single-celled creatures. Before now, small RNA could only be ... in a natural setting may make it possible finally ...
... Jersey Chapter of the American Society of Civil Engineers ... to John Schuring, Stabile Professor for Innovation and Technology ... expert, contact Sheryl Weinstein at 973-596-3436.) Schuring, ... has 35 years of experience in the areas of ...
... Jersey Chapter of the American Society of Civil Engineers ... to John Schuring, Stabile Professor for Innovation and Technology ... expert, contact Sheryl Weinstein at 973-596-3436.) Schuring, ... has 35 years of experience in the areas of ...
Cached Biology News:MIT reels in RNA surprise with microbial ocean catch 2MIT reels in RNA surprise with microbial ocean catch 3Civil engineers name NJIT's John Schuring Educator of Year 2Civil engineers name NJIT's John Schuring Educator of Year Award 2
MOUSE ANTI RAT RT1Bu Immunogen: Rat thymocyte membrane glycoproteins...
RABBIT ANTI HUMAN CYTOCHROME P450 1A1/2 Immunogen: Purified human CYP1A2 expressed in E.Coli ...
RABBIT ANTI HUMAN APP (KP1 DOMAIN) Immunogen: Synthetic peptide composed of amino acids 292-312 from the KPI domain of human APP....
... (CMV) pp65 Antigenemia Immunofluorescence Assay (IFA) is ... matrix protein pp65 of CMV in isolated ... Erythrocyte Lysis Buffer - ... mL of buffered ammonium chloride. (NH4CL) ...
Biology Products: